Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results
Quoin Pharmaceuticals (NASDAQ: QNRX) reported Q3 2024 developments and financial results. The company initiated a clinical study for QRX003 in Peeling Skin Syndrome in New Zealand and expanded its Netherton Syndrome trials with two new UK sites. Financial results showed a net loss of $2.3 million for Q3 2024, compared to $1.9 million in Q3 2023. Cash position stands at $10.3 million, expected to fund operations into late 2025. The management team made significant insider share purchases, demonstrating confidence in the company's trajectory.
Quoin Pharmaceuticals (NASDAQ: QNRX) ha riportato sviluppi e risultati finanziari per il terzo trimestre del 2024. L'azienda ha avviato uno studio clinico per QRX003 nella sindrome della pelle che si sfalda in Nuova Zelanda e ha ampliato i suoi studi sulla sindrome di Netherton con due nuovi siti nel Regno Unito. I risultati finanziari hanno mostrato una perdita netta di 2,3 milioni di dollari per il terzo trimestre del 2024, rispetto ai 1,9 milioni di dollari del terzo trimestre del 2023. La posizione di cassa è di 10,3 milioni di dollari, prevista per finanziare le operazioni fino a fine 2025. Il team di gestione ha effettuato acquisti significativi di azioni da parte di insider, dimostrando fiducia nella traiettoria dell'azienda.
Quoin Pharmaceuticals (NASDAQ: QNRX) informó sobre desarrollos y resultados financieros del tercer trimestre de 2024. La compañía inició un estudio clínico para QRX003 en el síndrome de piel descamativa en Nueva Zelanda y amplió sus ensayos sobre el síndrome de Netherton con dos nuevos sitios en el Reino Unido. Los resultados financieros mostraron una pérdida neta de 2,3 millones de dólares para el tercer trimestre de 2024, en comparación con 1,9 millones de dólares en el tercer trimestre de 2023. La posición de efectivo se sitúa en 10,3 millones de dólares, que se espera financie las operaciones hasta finales de 2025. El equipo de gestión realizó compras significativas de acciones por parte de insiders, demostrando confianza en la trayectoria de la empresa.
퀀 제약 (NASDAQ: QNRX)은 2024년 3분기 발전 상황 및 재무 결과를 보고했습니다. 이 회사는 뉴질랜드에서 벗겨지는 피부 증후군에 대한 QRX003 임상 연구를 시작했으며, 영국에 두 개의 새로운 사이트로 네더턴 증후군 시험을 확장했습니다. 재무 결과는 2024년 3분기에 230만 달러의 순손실을 기록했으며, 이는 2023년 3분기 190만 달러에 비해 증가한 것입니다. 현금 잔액은 1,030만 달러로, 2025년 말까지의 운영 자금을 지원할 것으로 예상됩니다. 관리팀은 내부자 주식 구매를 크게 늘려 회사의 성장 방향에 대한 신뢰를 나타냈습니다.
Quoin Pharmaceuticals (NASDAQ: QNRX) a rapporté des développements et des résultats financiers pour le troisième trimestre 2024. L'entreprise a lancé une étude clinique pour QRX003 dans le syndrome de peau pelée en Nouvelle-Zélande et a élargi ses essais sur le syndrome de Netherton avec deux nouveaux sites au Royaume-Uni. Les résultats financiers ont montré une perte nette de 2,3 millions de dollars pour le troisième trimestre 2024, par rapport à 1,9 million de dollars au troisième trimestre 2023. La position de liquidité s'élève à 10,3 millions de dollars, prévue pour financer les opérations jusqu'à fin 2025. L'équipe de direction a réalisé des achats significatifs d'actions par des initiés, démontrant sa confiance dans la trajectoire de l'entreprise.
Quoin Pharmaceuticals (NASDAQ: QNRX) berichtete über Entwicklungen und finanzielle Ergebnisse für das 3. Quartal 2024. Das Unternehmen hat eine klinische Studie für QRX003 im Peeling Skin Syndrome in Neuseeland initiiert und seine Netherton-Syndrom-Studien mit zwei neuen Standorten im Vereinigten Königreich erweitert. Die finanziellen Ergebnisse zeigten einen Nettoverlust von 2,3 Millionen US-Dollar für das 3. Quartal 2024, im Vergleich zu 1,9 Millionen US-Dollar im 3. Quartal 2023. Die Liquiditätsposition beträgt 10,3 Millionen US-Dollar und soll die Betriebe bis Ende 2025 finanzieren. Das Management-Team hat bedeutende Insider-Anteile erworben, was das Vertrauen in den Verlauf des Unternehmens demonstriert.
- Cash position of $10.3 million sufficient to fund operations into late 2025
- Expansion of clinical trials with two new UK sites for Netherton Syndrome
- Significant insider share purchases by entire management team
- Initiation of first formal clinical study for Peeling Skin Syndrome
- Increased net loss to $2.3M in Q3 2024 from $1.9M in Q3 2023
- Higher nine-month net loss of $6.7M compared to $6.6M in previous year
Insights
The Q3 2024 financial results reveal a concerning trend with net losses widening to
The expansion into Peeling Skin Syndrome (PSS) represents a strategic diversification of QRX003's potential market, though it adds to operational costs. The significant insider purchases by the entire management team is a positive signal, but must be weighed against the company's micro-cap status (
The initiation of the first formal clinical study for Peeling Skin Syndrome represents a significant opportunity in an untapped market with no existing approved treatments. The expansion of Netherton Syndrome trials to additional UK sites strengthens the clinical development program, potentially accelerating patient recruitment and data collection.
The dual-indication strategy for QRX003 demonstrates efficient resource utilization by leveraging a single asset across multiple rare disease indications. However, investors should note that early-stage clinical programs, especially in rare diseases, face significant development risks and typically require substantial time and capital before reaching commercialization.
Quoin Initiates Peeling Skin Syndrome Clinical Program
Further Expansion of International Reach for Netherton Syndrome Clinical Trials
Significant Insider Share Purchases by the Entire Management Team
ASHBURN, Va., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical-stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today provides a business update and announces financial results for the three and nine months ended Sept. 30, 2024.
Quoin CEO Dr. Michael Myers said, “The third quarter has been marked by notable achievements, including expanding the clinical reach of our lead product QRX003 into Peeling Skin Syndrome. We are now initiating an investigator-led clinical study in New Zealand to evaluate QRX003 for Peeling Skin Syndrome, for which there is no approved treatment or cure. This is the first step in a planned series of new indications for QRX003 and we believe this will be the first ever formal clinical study for Peeling Skin Syndrome. We have also continued to make real progress on the international expansion of our ongoing Netherton Syndrome clinical program with the announcement of the opening of two additional sites in the United Kingdom at recognized centers of clinical excellence. We look forward to announcing additional expansion into other countries in the future. Finally, the significant insider purchases made by the entire Quoin management team is a clear reflection of our strong belief and confidence in Quoin’s growth trajectory and long-term value creation. As we continue our commitment to the rare disease community, our focus remains on delivering life-changing treatments for underserved patient populations. We are proud of the advancements we’ve made and look forward to the upcoming milestones in our clinical development programs.”
Recent Corporate Highlights
- Peeling Skin Syndrome (PSS) Study: In August, Quoin announced the planned initiation of an investigator-led clinical study in New Zealand for QRX003 in pediatric patients with Peeling Skin Syndrome. This rare genetic condition currently has no approved treatments or cures. The first clinical site and patient have been identified, and Quoin is actively evaluating additional clinical sites in other countries.
- Insider Share Purchases: In September, Quoin’s CEO, COO and CFO made significant insider share purchases, signaling strong leadership confidence in the company’s growth trajectory.
- Netherton Syndrome Clinical Trials Expansion: Quoin continued its efforts to broaden the clinical trials for QRX003 as a potential treatment for Netherton Syndrome. In October 2024, the company announced the opening of two additional clinical sites in the United Kingdom, recognized centers of excellence for Netherton Syndrome, with plans to further expand in Western and Eastern Europe. The UK sites will operate under Quoin’s open Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA).
Financial Highlights
- Cash Position: Quoin had approximately
$10.3 million in cash, cash equivalents and marketable securities as of Sept. 30, 2024. This is expected to fund the Company’s operations into late 2025. - Net Loss: For the quarter ended Sept. 30, 2024, Quoin reported a net loss of approximately
$2.3 million compared to a net loss of approximately$1.9 million for the same period in 2023. For the nine months ended Sept. 30, 2024, the net loss was approximately$6.7 million compared to$6.6 million for the nine months ended Sept. 30, 2023.
Looking Ahead
Quoin is committed to advancing its clinical programs and remains focused on expanding the potential indications for QRX003. The company’s efforts in initiating clinical studies in additional rare disease indications, such as Peeling Skin Syndrome, and expanding its global clinical footprint for Netherton Syndrome trials are crucial steps in Quoin’s strategy to bring new treatments to patients with serious unmet needs.
The Company continues to evaluate M&A opportunities within the rare and orphan disease space as part of its long-term growth strategy.
Investors are encouraged to read the Company’s Report on Form 10-Q when it is filed with the Securities and Exchange Commission (the “SEC”), which will contain additional details about Quoin’s financial results as of and for the period ended Sept. 30, 2024.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.
Cautionary Note Regarding Forward Looking Statements
The Company cautions that statements in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “expect,” “intend,” “plan,” “anticipate,” “believe,” “look forward to,” and “will,” among others. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to: plans to initiate clinical study in peeling skin syndrome and the timing thereof, planned series of new indications for QRX003, look forward to announcing additional expansion into other countries in the future, advancing the Company’s clinical programs and expanding the potential indications for QRX003, initiating clinical studies in additional rare disease indication (such as Peeling Skin Syndrome), expanding the Company’s global clinical footprint for Netherton Syndrome trials, continuing to evaluate M&A opportunities in rare and orphan diseases, , plans to further expand in Western and Eastern Europe, the Company’s expected cash runway, and Quoin’s belief that its products in development collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the timing of the clinical studies may be delayed, the clinical studies may not generate the results anticipated, the Company being unable to expand into a number of EU countries as planned, the Company needing to raise additional funds sooner than planned, or the clinical studies not generating data which is sufficiently robust and comprehensive to support an NDA filing and the Company’s ability to obtain regulatory approvals. More detailed information about the risks and uncertainties affecting the Company is summarized in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
For further information:
PCG Advisory
Jeff Ramson
646-863-6893
jramson@pcgadvisory.com
-tables follow-
| QUOIN PHARMACEUTICALS, LTD. | |||||||||||
| Consolidated Balance Sheets | |||||||||||
| September 30, | December 31, | ||||||||||
| 2024 | 2023 | ||||||||||
| (Unaudited) | |||||||||||
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 3,116,750 | $ | 2,401,198 | |||||||
| Investments | 7,190,138 | 8,293,663 | |||||||||
| Prepaid expenses and other current assets | 190,541 | 591,034 | |||||||||
| Total current assets | 10,497,429 | 11,285,895 | |||||||||
| Prepaid expenses - long term | 383,390 | 300,000 | |||||||||
| Intangible assets, net | 508,334 | 583,334 | |||||||||
| Total assets | $ | 11,389,153 | $ | 12,169,229 | |||||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 222,636 | $ | 526,523 | |||||||
| Accrued expenses | 1,504,852 | 1,308,706 | |||||||||
| Accrued interest and financing expense | 1,146,251 | 1,146,251 | |||||||||
| Due to officers - short term | 600,000 | 600,000 | |||||||||
| Total current liabilities | 3,473,739 | 3,581,480 | |||||||||
| Due to officers - long term | 2,473,733 | 2,923,733 | |||||||||
| Total liabilities | $ | 5,947,472 | $ | 6,505,213 | |||||||
| Shareholders' equity: | |||||||||||
| Ordinary shares, no par value per share, 100,000,000 ordinary shares authorized at | $ | - | $ | - | |||||||
| September 30, 2024 and December 31, 2023, respectively - 5,049,720 (5,049,720 ADS's) ordinary shares issued and outstanding at September 30, 2024 and 987,220 (987,220 ADS's) at December 31, 2023 | |||||||||||
| Additional paid in capital | 58,296,199 | 51,867,336 | |||||||||
| Accumulated deficit | (52,854,518 | ) | (46,203,320 | ) | |||||||
| Total shareholders' equity | 5,441,681 | 5,664,016 | |||||||||
| Total liabilities and shareholders' equity | $ | 11,389,153 | $ | 12,169,229 | |||||||
| QUOIN PHARMACEUTICALS, LTD. | |||||||||||||||||||
| Consolidated Statements of Operations (unaudited) | |||||||||||||||||||
| Nine months ended September 30, | Three months ended September 30, | ||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||
| Operating expenses | |||||||||||||||||||
| General and administrative | $ | 4,590,936 | $ | 4,685,241 | $ | 1,357,715 | $ | 1,366,464 | |||||||||||
| Research and development | 2,532,468 | 2,475,596 | 1,170,287 | 758,759 | |||||||||||||||
| Total operating expenses | 7,123,404 | 7,160,837 | 2,528,002 | 2,125,223 | |||||||||||||||
| Other (income) and expenses | |||||||||||||||||||
| Unrealized (gain) loss | (23,043 | ) | 11,926 | (31,729 | ) | (2,119 | ) | ||||||||||||
| Realized and accrued interest income | (449,163 | ) | (536,068 | ) | (146,388 | ) | (196,425 | ) | |||||||||||
| Total other income | (472,206 | ) | (524,142 | ) | (178,117 | ) | (198,544 | ) | |||||||||||
| Net loss | $ | (6,651,198 | ) | $ | (6,636,695 | ) | $ | (2,349,885 | ) | $ | (1,926,679 | ) | |||||||
| Loss per ADS | |||||||||||||||||||
| Basic | $ | (1.63 | ) | $ | (7.61 | ) | $ | (0.47 | ) | $ | (1.95 | ) | |||||||
| Fully-diluted | $ | (1.63 | ) | $ | (7.61 | ) | $ | (0.47 | ) | $ | (1.95 | ) | |||||||
| Weighted average number of ADS's outstanding | |||||||||||||||||||
| Basic | 4,071,162 | 871,835 | 5,049,720 | 987,220 | |||||||||||||||
| Fully-diluted | 4,071,162 | 871,835 | 5,049,720 | 987,220 | |||||||||||||||
FAQ
What was Quoin Pharmaceuticals (QNRX) Q3 2024 net loss?
How much cash does QNRX have as of September 30, 2024?
What new clinical program did QNRX initiate in Q3 2024?
Where did QNRX expand its Netherton Syndrome clinical trials in 2024?
